There is substantial controversy regarding the causative role of amyloid b (Ab) deposition in Alzheimer's disease (AD). The cerebrovasculature plays an important role in the elimination of Ab from the brain and hypertension is a wellknown risk factor for AD. In spontaneously hypertensive stroke-prone rats (SHRSP), an animal model of chronic arterial hypertension, cerebral small vessel disease (CSVD) leads to age-dependent parenchymal Ab accumulation similar to that observed in AD. These data approve the neuropathological link between CSVD and AD, confirm the challenge that parenchymal Ab deposition is a specific marker for AD and disclose the meaning of SHRSP as valid experimental model to investigate the association between hypertension, CSVD, and Ab plaques.
Introduction
Accumulation of amyloid b (Ab) in the brain parenchyma is one of the pathological hallmarks of Alzheimer's disease (AD). There is substantial controversy regarding the causative role of amyloid deposition in AD. 1 In the majority of sporadic AD cases, Ab accumulation is thought to result from the failure of Ab clearance from the brain. 2 The cerebrovasculature plays an important role in the elimination of Ab from the brain, including receptor-mediated transport across the blood-brain barrier and perivascular drainage along vascular basement membranes and hypertension is a well-known risk factor for AD and Ab deposition. [3] [4] [5] We used the spontaneously hypertensive stroke-prone rats (SHRSP), an animal model of chronic arterial hypertension, to assess the role of cerebral small vessel disease (CSVD) in Ab accumulation. 6 Here we show that arterial hypertension and chronic small vessel disease This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
lead to an age-dependent parenchymal Ab accumulation similar to that observed in AD. These findings approve the neuropathological link between cerebrovascular diseases and AD and indicate that Ab accumulation is a nonspecific marker of tissue damage that can be elicited by hypertension, small vessel disease and AD or rather by the combined effects of all.
Efficient clearance of Ab requires healthy endothelial cell function and strong arterial pulsatility. Factors that affect vascular health, including age, hypercholesterolemia, and diabetes, are also risk factors for AD and have been shown to influence Ab deposition in the brain. 7 Hypertension is associated with CSVD and is a risk factor for vascular dementia (VaD). 8 CSVD pathology is commonly observed in AD brains and systolic hypertension has been shown to be associated with greater rate of cognitive decline in AD patients. 9 However, the link between hypertension, CSVD, and Ab deposition remains undefined.
Experimental models of AD rely on the expression of rare human familial mutations and often develop Ab pathology due to an overproduction of Ab peptides, rather than a failure of endogenous clearance mechanisms. 10 Furthermore, histopathologic findings characteristic for CSVD are missing in most AD models and inbred-provoked uniformity of animals does not adequately address the heterogeneity of human disease.
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In contrast to the broader assortment of experimental AD models, there are several available CSVD models generated by either (1) the induction of local and global hypoperfusion, (2) transgenic modifications leading to vasoconstrictions of cerebral arteries and small vessel wall damage, and by (3) provoked chronic hypertension. 12 Hypoperfusion models lack adequate reproducibility of human CSVD as they result in (1) scattered infarcts in distinct vascular territories and (2) a pathophysiological state found in patients with advanced disease of larger cerebral arteries (e.g., atherosclerosis). Such changes are not necessarily associated with small vessel wall changes and do not include hypertension, one of the main risk factors for CSVD.
SHRSP, an animal model of chronic arterial hypertension, develop a broad spectrum of CSVD histopathology, including early microvascular dysfunction with subsequent blood-brain barrier breakdown. 6 This results in degenerative small vessel wall changes with perivascular rupture and oozing bleeds and in many cases, reactive small vessel thrombosis with associated converging small infarcts all similar to that observed in hypertensive humans. 13, 14 However, whether SHRSP develop Ab deposition resulting from their risk profile of chronic hypertension and CSVD has not been reported. To address this, we investigated Ab pathology in the brains of 88 male SHRSP and 44 age-matched male Wistar rats using conventional histology including hematoxylin eosin (H&E) and Congo red staining and by immunohistochemistry using various anti-Ab antibodies. 
Material and Methods

Animals
Histology and immunocytochemistry
Rats and mice were transcardially perfused with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA), brains were removed and sectioned (30 lm thickness). Rodent brain tissues were processed for hematoxylin eosin (H&E) and Congo red staining. For Ab immunocytochemistry, brain sections were pretreated with either citrate buffer (65°C, 30 min) or formic acid (70-98%, 3-5 min), blocked with 10% donkey serum or 15% goat serum (Sigma, St. Louis, MO), and incubated overnight at 4°C with STL-FITC (Axxora, 1:500; Loerrach, Germany), anti-rodent-Ab (Covance, 1:500; Dedham, MA) or anti-human-Ab (Covance, clone 4G8, 1:500, DakoCytomation (Glostrup, Denmark), clone 6F3D, 1:500, Millipore (Billerica, MA), anti-Ab 1-17 1:500). For fluorescent immunolabeling, sections were developed using Cy3-donkeyanti-rabbit-IgG (Dianova, 1:500; Hamburg, Germany) or Alexa Fluor 594-anti-mouse-IgG (Invitrogen, 1:200; Carlsbad, CA), and rat sections were stained with 4′,6-diamidino-2-phenylindole (DAPI) (20 min, room temperature). Enzyme-linked immunocytochemistry was developed using biotinylated anti-mouse-IgG (Vector Labs, 1:500; Burlingame, CA) with nickel-enhanced diaminobenzidine as chromogen. To verify staining specificity, tissues were incubated with Cy5-donkey-anti-rat-IgG (Dianova, 1:500) to detect IgG or with anti-human-Ab (clone 4G8) that was preabsorbed with human Ab40 (Cambridge Biosciences, Cambridge, U.K., 25 lmol/L).
Results and Discussion
Sixteen out of 88 SHRSP (18%) showed deposition of parenchymal Ab plaques while cortical regions were affected in 69%, basal ganglia in 44%, hippocampus formation in 31% and thalamus and corpus callosum, respectively, in 6% of the Ab positive animals (Figs. 1, 2,  S1 ). Ab positive deposits did not colocalize with IgG or DAPI (Figs. 1F, H, and I, 2B, F, G, and J), suggesting that the staining was not due to leakage of the blood-brain barrier or nonspecific cellular labeling. These deposits were morphologically comparable to parenchymal Ab accumulations detectable in transgenic mouse models of AD and human AD (Fig. 3) and could be demonstrated specifically using various anti-Ab antibodies simultaneously applied to AD mice (Figs. 1C, 2C and D, 3A and D-F) . Age of the SHRSP had a significant effect on Ab deposition with a nearly threefold increase in affected animals from about 9% in the younger groups (age 12-31 weeks, four of 45 SHRSP were affected by parenchymal Ab plaques) to about 28% in the aged cohort (age 32-44 weeks, 12 of 43 SHRSP were affected by parenchymal Ab plaques); P < 0.05, univariate analysis of variance. Thus, 12 (75%) out of the 16 SHRSP affected by parenchymal Ab deposits were 32 weeks or even older with the highest prevalence of parenchymal Ab positivity in the oldest age group (40-44 weeks, 9 (56%) out of all 16 SHRSP with Ab plaques). Single deposition surrounded small vessel walls (Fig. S1A) .
Age-matched controls exhibited no parenchymal Ab deposition (data not shown) and no staining was observed following preabsorption of the anti-Ab antibody with purified Ab peptides, confirming the specificity of the staining (Fig. 3F) .
Within the growing burden of dementia in the elderly AD is the most common and VaD a frequent subtype of dementia, respectively. Age and hypertension are among common risk factors for AD, VaD, and CSVD. Aging and hypertension are associated with morphological and functional changes in the cerebral vasculature, including increased arterial stiffness and tortuosity, abnormal inclu- DAPI (F, H, and I) , suggesting that the staining is not due to leakage of the blood-brain barrier or nonspecific cellular labeling. Ab deposits do colocalize with STL, as previously described 19 (H). STL -Solanum tuberosum lectin, endothelial marker, 20 DAPI -4′,6-diamidino-2-phenylindole, for DNA detection.
sions, splitting, duplication and thickening of the basement membrane, and microvascular dysfunction, as found in chronic hypertensive SHRSP. [15] [16] [17] Healthy maintenance of the neurovascular unit is important for transendothelial transport of Ab from the brain parenchyma. Furthermore, the efficiency of perivas- cular drainage of Ab correlated with the amplitude of arterial pulsations. 18 Our present findings that endogenous parenchymal Ab deposits in the brains of SHRSP, but not in aged-matched controls, suggests that hypertension accelerates the age-dependent failure of mechanisms that remove Ab from the brain. These data provide additional support for a link between cerebrovascular health, AD, and parenchymal Ab accumulation, challenge the notion that Ab parenchymal deposition is a specific marker for AD and disclose the meaning of SHRSP as valid experimental model to investigate the association between hypertension, CSVD, and Ab plaques.
Limitations and perspectives
Major limitations of this study include the lack of a broader method spectrum to prove parenchymal amyloid accumulations in SHRSP and, the absent ability of the used antibodies to distinguish between different forms of Ab. However, promising data concerning elevated expressions of preliminary forms of fibrillar Ab plaques in already young SHRSP are under progress.
Our ongoing work now focusses on the detailed understanding of the link between hypertension, age and a possible (1) failure of enzymatic amyloid degradation, (2) diminution of Ab clearance across the BBB, and (3) along vascular basement membranes. Additionally, a closer look at the contribution of further vascular risk factors to that pathological interplay between small cerebrovascular damage, age, and parenchymal Ab load is planned in SHRSP.
